<DOC>
	<DOCNO>NCT02366143</DOCNO>
	<brief_summary>This randomize , open-label study evaluate safety efficacy Atezolizumab ( MPDL3280A ) combination carboplatin paclitaxel without bevacizumab compare treatment carboplatin plus ( + ) paclitaxel bevacizumab chemotherapy-naïve patient Stage IV non-squamous non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Phase III Study MPDL3280A ( Anti-PD-L1 Antibody ) Combination With Carboplatin + Paclitaxel With Without Bevacizumab Patients With Stage IV Non-squamous Non-small Cell Lung Cancer IMpower 150</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>18 year age old Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically cytologically confirm , treatmentnaïve Stage IV nonsquamous NSCLC Previously obtain archival tumor tissue tissue obtain biopsy screen Measurable disease define RECIST v1.1 Adequate hematologic end organ function Active untreated central nervous system ( CNS ) metastases Malignancies NSCLC within 5 year prior randomization , exception negligible risk metastasis death treat expect curative outcome Pregnant lactate woman History autoimmune disease History idiopathic pulmonary fibrosis , organize pneumonia , drug induce pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest Computed Tomography ( CT ) scan . History radiation pneumonitis radiation field ( fibrosis ) permit . Positive test Human Immunodeficiency Virus ( HIV ) Active hepatitis B hepatitis C Prior treatment CD137 agonists immune checkpoint blockade therapy , anti PD1 , antiPDL1 therapeutic antibody Severe infection within 4 week prior randomization Significant history cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>